GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

Tesla boss Elon Musk seems to be on a mission to conquer the world, and even Mars. But his odd-hour rants, alleged Nazi ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and full year 2024 earnings call. At this time, all lines are in a listen only mode. Following the presentation, we will ...

Blessing Outpatient Behavioral Health Services is offering a new option for depression. As many as 40% of people with depression can find no relief for their condition.

Elon Musk discussed his use of ketamine for depression during an interview, claiming it helps him combat negative mental ...

Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.